Dermatology · Indiana
Dermatology and skin studies in Indiana
39 studies have at least one recruiting site in Indiana. Skin studies test treatments for conditions such as psoriasis, eczema, acne, alopecia, vitiligo and hidradenitis suppurativa, from creams to tablets and injections.
39 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Plainfield, IN + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Sitryx Therapeutics Ltd
- Location
- Plainfield, IN + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Plainfield, IN + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- Indianapolis, IN + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Sagimet Biosciences Inc.
- Location
- Indianapolis, IN + 17 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Pfizer
- Location
- Indianapolis, IN + 11 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2/Phase 3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc.
- Location
- Indianapolis, IN + 26 other US sites
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Indianapolis, IN + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie
- Location
- Indianapolis, IN + 29 other US sites
- Eligibility basics
- Ages 12–63
- RecruitingPhase 2
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Spyre Therapeutics, Inc.
- Location
- Indianapolis, IN + 6 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Evansville, IN + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- Indianapolis, IN + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Indianapolis, IN + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- Indianapolis, IN + 6 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Evansville, IN + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Novartis Pharmaceuticals
- Location
- Indianapolis, IN + 23 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- New Albany, IN + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Novartis Pharmaceuticals
- Location
- Indianapolis, IN + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Indianapolis, IN + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Incyte Corporation
- Location
- West Lafayette, IN + 15 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Eli Lilly and Company
- Location
- Indianapolis, IN + 17 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development, LLC
- Location
- Indianapolis, IN + 5 other US sites
- Eligibility basics
- Ages 3+
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- Indianapolis, IN + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Clarksville, IN + 29 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Do I need a diagnosis to join a skin study?
Usually yes, and the site will confirm it at screening. Some studies also recruit people without the condition as a comparison group.